Bank of New York Mellon’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Bank of New York Mellon’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,078	Closed	-$1.05K	–	4445
2023 Q3	$1.05K	Hold	12,078	–	–	﹤0.01%	4339
2023 Q2	$6.76K	Hold	12,078	–	–	﹤0.01%	4358
2023 Q1	$13.8K	Hold	12,078	–	–	﹤0.01%	4334
2022 Q4	$13.5K	Hold	12,078	–	–	﹤0.01%	4393
2022 Q3	$25K	Hold	12,078	–	–	﹤0.01%	4423
2022 Q2	$16K	Hold	12,078	–	–	﹤0.01%	4517
2022 Q1	$20K	Hold	12,078	–	–	﹤0.01%	4614
2021 Q4	$13K	Hold	12,078	–	–	﹤0.01%	4608
2021 Q3	$36K	Hold	12,078	–	–	﹤0.01%	4474
2021 Q2	$36K	Sell	12,078 -34,468	-74%	-$105K	﹤0.01%	4364
2021 Q1	$152K	Sell	46,546 -937	-2%	-$3.85K	﹤0.01%	4111
2020 Q4	$195K	Buy	47,483 +6,244	+15%	+$36K	﹤0.01%	3983
2020 Q3	$223K	Buy	41,239 +12,597	+44%	+$72.6K	﹤0.01%	3811
2020 Q2	$192K	Buy	28,642 +6,312	+28%	+$30.9K	﹤0.01%	3805
2020 Q1	$71K	Buy	22,330 +345	+2%	+$1.84K	﹤0.01%	3918
2019 Q4	$154K	Hold	21,985	–	–	﹤0.01%	3965
2019 Q3	$84K	Buy	21,985 +9,840	+81%	+$33.3K	﹤0.01%	4046
2019 Q2	$46K	Sell	12,145 -10,963	-47%	-$36.4K	﹤0.01%	4130
2019 Q1	$83K	Buy	+23,108	New	+$170K	﹤0.01%	4034

Other funds holding RVLP

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of New York Mellon's RVLP Position: Q4 2023 in Review

Bank of New York Mellon sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 12,078 shares — an estimated $1.05K sold.

Bank of New York Mellon first reported a position in RVLP in Q1 2019 and held it in 19 quarters. The position peaked at $223K in Q3 2020. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

Bank of New York Mellon reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Bank of New York Mellon sold 12,078 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $1.05K.
Bank of New York Mellon first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q1 2019 and held it in 19 quarters.
Bank of New York Mellon's RVL Pharmaceuticals plc Ordinary Shares position peaked at $223K in Q3 2020.
3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.